Olema Pharmaceuticals, Inc.

NASDAQ: OLMA · Healthcare · Biotechnology

PublicHQ San Francisco, CA · San FranciscoCIK 0001750284Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 60DQ —GM —SS 58

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$162.5M

Employees

137

as of 2026-08-10

Market cap

$1.1B

as of 2026-08-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$162.5M-$162.5M2025

Operating income-$178.7M-$178.7M2025

Total assets$533.4M$533.4M2025

Liabilities$54.9M$54.9M2025

Equity$478.6M$478.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Olema Pharmaceuticals, Inc.’s financial profile?

Olema Pharmaceuticals, Inc. earned -$162.5M in FY2025 net income.

Peers · Healthcare

Corvus Pharmaceuticals, Inc.——Latigo Biotherapeutics Inc.——Seaport Therapeutics, Inc. Common Stock——Replimune Group, Inc.——Alto Neuroscience, Inc.——Lumexa Imaging Holdings, Inc. Common Stock——

Neighbors

San Francisco →

Visa Inc.$40.0B86A Wells Fargo & Company$85.1B55C Salesforce, Inc.$41.5B80B+Uber Technologies, Inc.$52.0B71B Prologis, Inc.$8.8B66B Cloudflare, Inc.$2.2B59C

Key facts

CEOSean Bohen

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Francisco, CA

ExchangeNASDAQ: OLMA

Employees137

IPO date2020-11-19

Latest filings

8-K2026-08-13 8-K2026-08-10 10-Q2026-08-10 8-K2026-06-23 8-K2026-05-26 8-K2026-05-21 10-Q2026-05-12 8-K2026-05-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.